Search research articles
Contact Us
Filters
Showing results (161-170 of 323) with videos related to
Page
of 33
Sort By:
Clinical Pharmacokinetics
|
August 19, 1999
Intravesical drug delivery. Pharmacokinetic and clinical considerations
M S Highley, A T van Oosterom, R A Maes, et al.
European Journal of Pharmacology
|
July 4, 1995
The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects
L Groenink, J Van der Gugten, P M Verdouw, et al.
The European Journal of Neuroscience
|
November 1, 1996
5-HT1A receptor agonist flesinoxan enhances Fos immunoreactivity in rat central amygdala, bed nucleus of the stria terminalis and hypothalamus
J C Compaan, L Groenink, J van der Gugten, et al.
Nuklearmedizin. Nuclear Medicine
|
February 18, 2010
Impact of FDG PET on the management of TBC treatment. A pilot study
M Sathekge, A Maes, M Kgomo, et al.
Biological Mass Spectrometry
|
August 1, 1991
The analysis of trenbolone and the human urinary metabolites of trenbolone acetate by gas chromatography/mass spectrometry and gas chromatography/tandem mass spectrometry
D de Boer, M E Gainza Bernal, R D van Ooyen, et al.
European Journal of Pharmacology
|
April 18, 1997
Pretreatment with 5-HT1A receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus
J C Compaan, L Groenink, J Van der Gugten, et al.
Acta Oto-Laryngologica. Supplementum
|
January 1, 1986
The use of a SQUID magnetometer in the study and development of normal and artificial middle ear
W L Rutten, D Bakker, J H Kuit, et al.
Journal of Nuclear Medicine Technology
|
October 2, 1998
Nuclear cardiology, Part III: Scintigraphic evaluation of cardiac perfusion
H Everaert, A Maes, A S Hambye, et al.
The Annals of Thoracic Surgery
|
January 22, 1998
PET scan predicts recovery of left ventricular function after coronary artery bypass operation
W J Flameng, B Shivalkar, B Spiessens, et al.
Arzneimittel-Forschung
|
January 1, 1982
Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients
J G Leferink, W van den Berg, I Wagemaker-Engels, et al.
Page
of 33
Search research articles
Search
Showing results (161-170 of 323) with videos related to
Sort By:
Page
of 33
Clinical Pharmacokinetics
|
August 19, 1999
Intravesical drug delivery. Pharmacokinetic and clinical considerations
M S Highley, A T van Oosterom, R A Maes, et al.
European Journal of Pharmacology
|
July 4, 1995
The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects
L Groenink, J Van der Gugten, P M Verdouw, et al.
The European Journal of Neuroscience
|
November 1, 1996
5-HT1A receptor agonist flesinoxan enhances Fos immunoreactivity in rat central amygdala, bed nucleus of the stria terminalis and hypothalamus
J C Compaan, L Groenink, J van der Gugten, et al.
Nuklearmedizin. Nuclear Medicine
|
February 18, 2010
Impact of FDG PET on the management of TBC treatment. A pilot study
M Sathekge, A Maes, M Kgomo, et al.
Biological Mass Spectrometry
|
August 1, 1991
The analysis of trenbolone and the human urinary metabolites of trenbolone acetate by gas chromatography/mass spectrometry and gas chromatography/tandem mass spectrometry
D de Boer, M E Gainza Bernal, R D van Ooyen, et al.
European Journal of Pharmacology
|
April 18, 1997
Pretreatment with 5-HT1A receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus
J C Compaan, L Groenink, J Van der Gugten, et al.
Acta Oto-Laryngologica. Supplementum
|
January 1, 1986
The use of a SQUID magnetometer in the study and development of normal and artificial middle ear
W L Rutten, D Bakker, J H Kuit, et al.
Journal of Nuclear Medicine Technology
|
October 2, 1998
Nuclear cardiology, Part III: Scintigraphic evaluation of cardiac perfusion
H Everaert, A Maes, A S Hambye, et al.
The Annals of Thoracic Surgery
|
January 22, 1998
PET scan predicts recovery of left ventricular function after coronary artery bypass operation
W J Flameng, B Shivalkar, B Spiessens, et al.
Arzneimittel-Forschung
|
January 1, 1982
Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients
J G Leferink, W van den Berg, I Wagemaker-Engels, et al.
Page
of 33